Forte Biosciences FB102 shows vitiligo improvement in phase 1b trial
Go back to Forte Biosciences FB102 shows vitiligo improvement in phase 1b trial| (NASDAQ: FBRX) | Delayed: 76.99 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $76.99 | 52 Week High | $ | |||
| Open | $76.99 | 52 Week Low | $ | |||
| Day High | $76.99 | P/E | N/A | |||
| Day Low | $76.99 | EPS | $ | |||
| Volume | 2,458,907 | |||||

